QIAGEN N.V. — 2020 Form 20-F
Reporting period: Fiscal year ended December 31, 2020. Although the request metadata refers to 2020 Q4, this is an annual report; the supplied filing text does not provide a clear standalone fourth-quarter income or cash-flow statement. Financial statements are prepared under U.S. GAAP and audited. The auditor issued unqualified opinions on the financial statements and internal control over financial reporting; NeuMoDx was excluded from management’s internal-control assessment for its first year after acquisition.
Business context and key financial metrics
QIAGEN is a Netherlands-based global provider of molecular testing products, including consumables, instruments, diagnostic solutions and bioinformatics. It serves Molecular Diagnostics and Life Sciences customers and operates as one reportable segment. COVID-19 testing demand was a major driver of 2020 results.
| Metric | 2020 | 2019 | Change / context |
|---|---|---|---|
| Net sales | $1,870.3 million | $1,526.4 million | Up 23%; favorable currency movements contributed 2 percentage points |
| Gross profit / gross margin | $1,232.7 million / 65.9% | $1,005.3 million / 65.9% | Margin unchanged |
| Operating income (loss) | $386.4 million | $(26.1) million | Operating margin was 20.7%, versus (1.7)% |
| Net income (loss) | $359.2 million | $(41.5) million | Basic EPS $1.57; diluted EPS $1.53 |
| Cash provided by operating activities | $457.8 million | $330.8 million | Up from prior year |
| Cash used in investing activities | $(443.3) million | $(222.3) million | Included acquisitions, intangible assets and capacity investment |
| Cash used in financing activities | $(50.1) million | $(639.1) million | Included debt and warrant transactions and share repurchases |
| Cash and cash equivalents | $598.0 million | $623.6 million | Short-term investments were $117.2 million at year-end 2020 |
| Working capital | $1,052.2 million | $618.9 million | Current assets less current liabilities |
| Long-term debt, including current portion | $1,922.7 million | $1,706.4 million | $42.5 million current at year-end 2020 |
Material changes versus 2019
- COVID-19 products generated $617.9 million, or 33% of 2020 sales, versus $143.3 million, or 9%, in 2019. Non-COVID-19 sales declined 9% to $1,252.4 million.
- Consumables and related revenue increased 19% to $1,615.4 million; instrumentation increased 48% to $254.9 million. Instrumentation grew faster, but its lower-margin mix and higher material costs were offset by lower acquisition-related amortization, leaving gross margin flat.
- Sales grew 23% in both Molecular Diagnostics and Life Sciences. By product group, sample technologies rose 47% and PCR/nucleic acid amplification rose 62%; diagnostic solutions declined 1%, genomics/NGS declined 10%, and other revenue declined 26%.
- Operating results improved substantially from 2019, which included $140.0 million of long-lived asset impairments and significant restructuring costs. 2020 still included $150.0 million of restructuring, acquisition, integration and other net expenses.
- Net income also benefited from $114.3 million of other income, net, including a $123.3 million gain related to the sale of the ArcherDX investment. This was partly offset by the failed Thermo Fisher transaction and related costs.
- Operating cash flow increased, while investing cash outflows rose, principally due to the NeuMoDx acquisition, Formulatrix digital-PCR milestone payments, and production-capacity spending. Working capital rose, with inventory increasing to $291.2 million from $170.7 million.
Outlook, commentary, risks and unusual items
- Outlook: The filing does not provide a clear numerical full-year 2021 sales or earnings guidance in the supplied text. Management said it expected operations, existing cash and available financing to fund planned operations and expansion during the coming year, and anticipated further NeuMoDx integration costs in 2021. It also expected increased R&D spending for product development and regulatory approvals.
- Failed acquisition attempt: Thermo Fisher’s proposed acquisition did not meet the revised minimum acceptance threshold. QIAGEN recorded $125.5 million of related 2020 expenses, including a $95.0 million expense reimbursement paid to Thermo Fisher.
- Acquisitions and investment: QIAGEN acquired the remaining 80.1% of NeuMoDx in September 2020. The preliminary purchase-price allocation included $157.2 million of acquired intangible assets and $157.6 million of goodwill. The company also paid $135.9 million in remaining Formulatrix digital-PCR milestone payments during 2020.
- Debt and liquidity: QIAGEN issued $500 million of zero-coupon convertible notes due 2027 and reported $1.9 billion of debt. It had an undrawn €400 million ESG-linked revolving facility and other undrawn credit lines at year-end. Debt covenants, refinancing needs and the transition from LIBOR/EURIBOR benchmarks remain risks.
- Other risks and contingencies: Key exposures include dependence on new-product adoption and COVID-related demand, manufacturing or supplier disruptions, regulatory approvals and reimbursement, competition, foreign exchange, cybersecurity and privacy, acquisition integration, and tax uncertainty. Litigation accruals were $5.2 million; management estimated possible losses of $4.7 million to $16.3 million. Unrecognized tax benefits were $100.1 million, and contingent acquisition-related payments could total up to $26.6 million.
- Shareholder returns: QIAGEN stated it did not intend to pay regular dividends. It repurchased 1.3 million shares for $64.0 million in 2020; the announced program ended in December.
Important facts for investors to verify
- How much of the 2020 growth and earnings level is recurring, given that COVID-19 products were 33% of sales and non-COVID sales fell 9%?
- How should earnings be assessed after separating the $123.3 million ArcherDX-related gain from operating performance and considering the $125.5 million failed-tender-offer expense?
- What are the repayment, conversion, dilution and interest implications of the $1.9 billion debt balance, including the 2027 convertible notes and outstanding warrants?
- Will NeuMoDx and QIAcuity adoption, manufacturing expansion and regulatory approvals deliver returns sufficient to support the acquired goodwill and intangible-asset values?
- What is the ultimate cash and earnings exposure from tax audits, contingent acquisition payments and pending litigation?